SPY381.72-1.91 -0.50%
DIA318.25+3.01 0.95%
IXIC12,609.16-310.99 -2.41%

BRIEF-Oxford Says Oxford/AstraZeneca COVID-19 Vaccine Effective Against UK B.1.1.7 'Kent' Strain

· 02/05/2021 08:08
BRIEF-Oxford Says Oxford/AstraZeneca COVID-19 Vaccine Effective Against UK B.1.1.7 'Kent' Strain

- Oxford University:

  • OXFORD VACCINE EFFECTIVE AGAINST MAJOR B.1.1.7 'KENT' CORONAVIRUS STRAIN CIRCULATING IN UK

  • PREPRINT OF ONGOING WORK TO ASSESS EFFECTIVENESS OF ITS VACCINE SHOWS VACCINE HAS SIMILAR EFFICACY AGAINST B.1.1.7 'KENT' CORONAVIRUS STRAIN

  • RESEARCHERS WHO DEVELOPED CHADOX1-NCOV 19 VACCINE HAVE FOUND THAT IT REMAINS EFFECTIVE AGAINST ONE OF NEW VARIANTS OF DISEASE

  • DATA FROM TRIALS OF CHADOX1 VACCINE IN UK INDICATE VACCINE ALSO PROTECTS AGAINST NOVEL VARIANT, B.1.1.7

  • BETWEEN 1 OCT-JAN 14, RESEARCHERS USED SWABS TAKEN FROM VOLUNTEERS WITH SYMPTOMATIC & ASYMPTOMATIC INFECTION ENROLLED IN PHASE II/III STUDY

  • VACCINE RESEARCHERS ARE ALREADY LOOKING AT WAYS TO MODIFY EXISTING VACCINES QUICKLY AND SIMPLY TO PROTECT AGAINST NEW VARIANTS

  • WORKING WITH ASTRAZENECA TO OPTIMISE PIPELINE REQUIRED FOR A STRAIN CHANGE SHOULD ONE BECOME NECESSARY

  • WORKING WITH ASTRAZENECA TO OPTIMISE PIPELINE REQUIRED FOR A STRAIN CHANGE SHOULD ONE BECOME NECESSARY

  • PROTECTION AGAINST SYMPTOMATIC INFECTION SIMILAR DESPITE LOWER NEUTRALISING ANTIBODY TITRES IN VACCINATED INDIVIDUALS AGAINST B.1.1.7 VARIANT THAN 'VICTORIA' STRAIN OF VIRUS

Further company coverage: AZN.L


((Reuters.Briefs@thomsonreuters.com;))